What is Xenon Pharmaceuticals Inc (XENE)?
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing precision therapies for neurological disorders. The company utilizes a genetics-driven approach to identify and develop treatments targeting ion channels and other molecular mechanisms implicated in rare and severe neurological diseases. Its pipeline includes product candidates aimed at conditions such as epilepsy, migraine, and neuropathic pain. Xenon Pharmaceuticals employs a combination of proprietary drug discovery platforms and translational science to advance its programs from early research through clinical development. The company collaborates with academic institutions and industry partners to support its research initiatives. Its operations encompass research and development activities, regulatory interactions, and clinical trial management. Xenon Pharmaceuticals is headquartered in Canada and operates within the biotechnology sector, contributing to advancements in targeted therapies for unmet medical needs.
Xenon Pharmaceuticals Inc Stock Price Today: Live Overview
The price today is shaped by the latest trading activity, with GEN Restaurant Group Inc currently at $55.82. It has fluctuated between $54.45 and $56.07, showing a daily change of +0.036%.
FAQ: Xenon Pharmaceuticals Inc (XENE)
What is the current price of XENE stock?
The latest price for Xenon Pharmaceuticals Inc is $55.82.
Does XENE pay dividends?
Xenon Pharmaceuticals Inc does not currently pay dividends.
Does XENE have a formal corporate presence or regional headquarters in the UAE?
Xenon Pharmaceuticals Inc operates primarily through its headquarters and does not have an official regional office or subsidiary in the UAE, operating via partners instead.
What is XENE best known for?
Xenon Pharmaceuticals Inc is most famous for its development of novel therapies for neurological disorders.
What assets are typically shown together with XENE?
Commonly shown alongside XENE: First Trust Eurozone AlphaDEX UCITS ETF, Immunocore Holdings plc, Hermes
Latest shares articles



